Vmbook Online ordering
Biotechnology
ALS Limited, together with its subsidiaries, engages in the development, manufacture, sale, and marketing of animal health products, ranches, and human health products in the United States, Australia, New Zealand, and internationally. It operates through three segments: Animal Health, Human Health, and All Other segments. The Animal Health segment offers nutritional feed supplements, vitamins, and minerals; vaccines and diagnostic kits; wound care and disinfectant products; and parasiticides and anthelmintics to the cattle, sheep, pig, poultry, and equine industries.
The Human Health segment provides vitamins and dietary supplements; Contract Manufacturing Services; and pharmaceuticals. The All Other segment comprises royalty investments, a minority investment in a New Zealand-based company that produces animal health and human health products, and corporate companies. The company was formerly known as Allied Minds Limited and changed its name to ALS Limited in December 2018. ALS Limited was founded in 1877 and is based in Sydney, Australia.
ALS Limited is a public company listed on the Sydney Stock Exchange (ASX) under the ticker symbol "ALS." For the fiscal year 2022, the company's revenue was AU$2.17 billion, a 12.1% increase from the previous year. Its net income was AU$126.9 million, a 24.9% increase from the previous year. The company's earnings per share (EPS) was AU$0.26, and its dividend yield was 4.44%.
ALS Limited's future growth is expected to be driven by its focus on developing innovative products and expanding its presence in global markets. The company has made strategic acquisitions and partnerships to expand its product portfolio and increase its market share. Additionally, the company has invested in research and development to develop new products and improve its manufacturing processes.
However, the company faces risks, including increasing competition in the animal health and human health markets and regulatory changes that may affect its product offerings. The ongoing pandemic has also impacted the company's business, as supply chain disruptions and reduced demand for some of its products have occurred.
As of March 2023, the consensus estimate for ALS Limited's fiscal year 2023 revenue is AU$2.43 billion, representing a 10.7% increase from the previous year. Its expected net income is AU$146.4 million, representing a 16.5% increase from the previous year. The company's expected EPS is AU$0.31, and its expected dividend yield is 4.4%.
Overall, ALS Limited is a well-established company in the animal health and human health markets, with a long history of growth and a strong presence in global markets. The company's focus on innovation and expansion is expected to continue to drive its growth in the future. Still, it faces risks related to competition and regulatory changes that investors should consider when evaluating the stock.